Cargando…
Immunotherapies for hepatocellular carcinoma
Cases of hepatocellular carcinoma (HCC) are rapidly rising. This is particularly the case in the Western world, as a result of increasing rates of chronic liver disease, secondary to lifestyle‐associated risk factors and the lack of an established screening programme for the general population. Trad...
Autores principales: | Liu, Justin K. H., Irvine, Andrew F., Jones, Rebecca L., Samson, Adel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817091/ https://www.ncbi.nlm.nih.gov/pubmed/34953051 http://dx.doi.org/10.1002/cam4.4468 |
Ejemplares similares
-
Immunotherapy in Hepatocellular Carcinoma
por: Fulgenzi, Claudia A. M., et al.
Publicado: (2021) -
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
por: Pinato, David J., et al.
Publicado: (2021) -
The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma
por: Sellers, Cortlandt M., et al.
Publicado: (2021) -
Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin
por: Wang, Xiumei, et al.
Publicado: (2020) -
Prognostic and predicted significance of Ubqln2 in patients with hepatocellular carcinoma
por: Luo, Yuan‐Deng, et al.
Publicado: (2020)